Dr. Ryan Matthew Pearson's lab at the University of Maryland Baltimore focuses on developing innovative nanoparticle-based therapies to combat severe inflammation and sepsis. Their research aims to enhance the body's innate immune response using drug-free nanoparticles that can improve survival rates in sepsis through a multimodal approach. This work addresses a critical gap in current sepsis treatments and seeks to offer new, effective solutions to improve patient outcomes.

Dr. Ling Li's lab at the University of Minnesota focuses on understanding the biochemical changes that lead to Alzheimer's disease and the effects of COVID-19 on the brain. The lab investigates how variations of the apolipoprotein E (APOE) gene and mitochondrial lipids interact to influence brain aging and cognitive function. They utilize advanced techniques to study brain pathology in aging and how infections like SARS-CoV-2 may exacerbate cognitive impairments.

Dr. Julia Tcw's lab at Boston University Medical Campus focuses on understanding the cellular mechanisms of Alzheimer's disease, especially as they relate to two critical components: astrocytes and microglia, which are types of brain cells. The lab investigates how genetic factors like the APOE4 variant affect cellular processes that lead to neurodegeneration. By studying human brain cells in the lab, they aim to identify new potential treatments for Alzheimer's disease, particularly by targeting the dysfunctions in brain cell nutrient processing and inflammation.

Dr. Mei He's lab at the University of Florida focuses on understanding how aging affects the relationship between the brain and muscles, especially in the context of space travel. By studying extracellular vesicles, which are small particles that carry information between cells, the lab aims to uncover potential therapies that could help prevent neurodegenerative diseases like Alzheimer's and Parkinson's. This research could lead to effective ways to keep astronauts healthier during long missions in microgravity and improve aging-related health on Earth as well.

Dr. Edwin S. Levitan's lab at the University of Pittsburgh focuses on understanding how neuropeptides, which are small protein-like molecules, help regulate important behaviors such as sleep and circadian rhythms. The lab uses advanced imaging techniques to study how these neuropeptides are released in the brain and how their release is influenced by different signals. This research is critical for revealing how neuropeptides contribute to the functioning of the nervous system, especially during behavioral changes and plasticity.

Dr. Jagdish Singh's lab focuses on developing new therapies for Alzheimer's Disease, a common neurodegenerative disorder. The lab is particularly interested in using gene therapy to increase levels of certain proteins, like APOE2 and VGF, that may protect brain function and improve cognitive abilities. They create specialized nanoparticles to deliver these therapeutic genes across the blood-brain barrier, aiming to enhance the effectiveness of treatments for Alzheimer's and related conditions.

Dr. Weiming Xia's lab at Boston University focuses on finding new treatments for Alzheimer's disease (AD) by analyzing large datasets from veterans' health records. The lab investigates how certain medications, particularly vasodilators, may slow the progression of AD and alleviate cognitive impairments. By combining big data analysis with experiments in mouse models, the lab aims to uncover potential therapies that can be quickly developed for patients.

The Birdsong lab at the University of Michigan focuses on understanding how opioid receptors in the brain affect pain and reward behaviors. By studying specific neurons in the medial thalamus, the lab aims to uncover the mechanisms behind both pain relief and heightened sensitivity to pain after opioid withdrawal. This research has important implications for improving pain management strategies and reducing the risk of opioid misuse.

Dr. Qin M. Chen's lab at the University of Arizona focuses on understanding how cells respond to oxidative stress, particularly in the context of heart failure. The research investigates the role of specific proteins in activating protective responses that could slow down or prevent heart damage. By exploring RNA methylation and protein translation mechanisms, the lab aims to uncover new strategies for addressing heart failure, a severe and costly health issue.

Dr. Gregory Cuny's lab at the University of Houston focuses on creating new treatments for cryptosporidiosis, a disease caused by parasitic protozoa that affects people, especially children and those with weakened immune systems. The lab is working on selective inhibitors that target a specific protein involved in the survival of these parasites. This research aims to improve treatment options for those infected, as current medications are limited and ineffective for certain populations.

Dr. Johannes Czernin's lab at UCLA focuses on enhancing the effectiveness of treatments for advanced prostate cancer. The research primarily revolves around understanding how different genetic and immunological factors influence responses to a specific type of targeted therapy known as PSMA-RPT, which can improve survival rates but often falls short of optimal results. By analyzing tumor characteristics and immune interactions, the lab aims to develop new combination therapies that address treatment resistance and improve patient outcomes.

Dr. Rocklin's lab focuses on understanding how proteins fold and remain stable, which is critical for their functions in biological systems. They develop innovative methods to measure the stability of thousands of proteins at once. This research can lead to enhancements in drug and vaccine development by predicting how genetic variations affect protein behavior and by creating smart models to guide these processes.

Dr. Bryan L. Roth's lab focuses on understanding how psychoactive drugs, like LSD, interact with specific receptors in the brain that are crucial for treating mental disorders. They use advanced techniques to study the structures of serotonin and Mas-related receptors to uncover how these drugs work at a molecular level. This research aims to improve drug design for conditions such as schizophrenia and chronic pain, leading to safer and more effective treatments.

Dr. Vincent H Tam's lab focuses on fighting multidrug-resistant bacteria that no longer respond to standard antibiotics. The lab is developing a precision medicine platform that can select effective combinations of antibiotics tailored to individual patients. This research is crucial as it aims to prevent a return to the pre-antibiotic era by finding new ways to use existing drugs more effectively.

Dr. Fernanda Laezza's lab focuses on understanding and treating psychiatric disorders by investigating brain circuits and their behaviors. The research emphasizes developing novel chemical probes that target specific protein interactions in neurons, particularly related to reward mechanisms. By studying how these probes influence neuronal activity, the team aims to uncover new therapeutic strategies for various mental health conditions.

Dr. Patrick Forcelli's lab focuses on understanding and controlling seizures in epilepsy by exploring the brain's basal ganglia and brainstem networks. They aim to identify and manipulate specific brain circuits that can suppress seizure activity, which is vital for patients who do not respond to traditional treatments. By using advanced techniques like optogenetics and electrophysiology, the lab seeks to uncover new interventions for better seizure control.

Dr. Rugang Zhang's lab is focused on understanding how cancer cells can evade treatment and promote tumor growth through a process called senescence. They specifically study the senescence-associated secretory phenotype (SASP), which involves the secretion of various factors by senescent cells that can contribute to therapy resistance in epithelial ovarian cancer. The lab aims to uncover the underlying mechanisms of this process, particularly through the role of certain proteins, and to develop new therapeutic strategies that target these pathways to improve treatment outcomes for patients.

Dr. Ki Ann Goosens leads a research lab focused on understanding how chronic stress affects decision-making processes in the brain. The lab studies the interactions between specific brain circuits and hormones like ghrelin, which play vital roles in determining how we weigh potential risks and rewards. Through innovative approaches such as optogenetics and pharmacological experiments, they aim to uncover the mechanisms that lead to altered decision-making in the context of psychiatric disorders such as depression and PTSD.

Dr. Lori L. Isom's lab focuses on understanding how certain genetic conditions, specifically linked to epilepsy, can lead to serious complications like Sudden Unexpected Death in Epilepsy (SUDEP). The lab studies the relationship between heart and brain function, using cutting-edge models such as transgenic rabbits that closely mimic human physiology. By exploring how specific gene changes affect both cardiac rhythms and breathing regulation during seizures, the lab aims to uncover new insights that could help prevent SUDEP and improve the lives of patients with epilepsy.

Dr. Salah-Uddin Ahmed's lab at Washington State University focuses on understanding the role of a protein called TAK1 in rheumatoid arthritis (RA). They study how TAK1 contributes to the inflammatory and invasive behaviors of synovial fibroblasts, which play a key role in RA pathology. The lab aims to develop targeted therapies using TAK1 inhibitors to improve treatment outcomes for patients suffering from this chronic disease.